Medtronic plc, the Fridley-based medical device powerhouse, reported 5.5% organic revenue growth to $8.81 billion in its fiscal second quarter of 2026, propelled by a 9.3% leap in cardiovascular sales. The standout performer: a cardiac ablation business that rocketed 71% year-over-year, fueled by innovations like the Affera pulsed field ablation system. Minnesota's economic engine hums as the company cements its lead in heart tech.